Category: Biotherapeutics Portfolio

  • Exelixis Acquires GamaMabs’ Oncology Antibody Program to Expand its Biotherapeutics Portfolio

    Shots: Exelixis to acquire GamaMabs’ AMHR2 Ab technology for $5M and additionally payment upon achieving certain milestones. Following the closing of the transaction, Exelixis will control GamaMabs’ AMHR2 franchise technology including all assets related to murlentamab (GM-102) The preclinical data support the potential of AMHR2 for novel oncology therapies and demonstrated the safety of an […]